4//SEC Filing
PROTEON THERAPEUTICS INC 4
Accession 0001104659-14-074955
$TARACIK 0001359931operating
Filed
Oct 28, 8:00 PM ET
Accepted
Oct 29, 7:35 PM ET
Size
33.0 KB
Accession
0001104659-14-074955
Insider Transaction Report
Form 4
Transactions
- Conversion
Series A Convertible Preferred Stock
2014-10-27−5,000,000→ 0 total→ Common Stock (375,608 underlying) - Exercise of In-Money
Common Stock
2014-10-27$4.60/sh+121,760$560,376→ 1,488,968 total - Conversion
Series A-1 Convertible Preferred Stock
2014-10-27−2,341,664→ 0 total→ Common Stock (179,903 underlying) - Purchase
Common Stock
2014-10-27$10.00/sh+200,000$2,000,000→ 200,000 total - Conversion
Common Stock
2014-10-27+1,167,208→ 1,367,208 total - Conversion
Series D Convertible Preferred Stock
2014-10-27−3,932,747→ 0 total→ Common Stock (247,810 underlying) - Exercise of In-Money
Warrants (Right to Buy)
2014-10-27−121,760→ 0 totalExercise: $4.60→ Common Stock (121,760 underlying) - Sale
Common Stock
2014-10-27$10.00/sh−56,038$560,380→ 1,432,930 total - Conversion
Series B Convertible Preferred Stock
2014-10-27−2,173,913→ 0 total→ Common Stock (168,680 underlying) - Conversion
Series C Convertible Preferred Stock
2014-10-27−2,436,437→ 0 total→ Common Stock (189,049 underlying) - Other
Option (Right to Purchase)
2014-10-27−1,389,064→ 0 total→ Series D Convertible Preferred Stock (87,527 underlying)
Footnotes (10)
- [F1]These shares were purchased in connection with the Issuer's initial public offering of Common Stock.
- [F10]Skyline had a right to purchase shares of Series D Convertible Preferred Stock under the Series D Purchase Agreement at a price of $0.588656, which right to purchase ceased to be exercisable upon the initial filing of the Issuer's registration statement for its initial public offering, and terminated upon the completion of the Issuer's initial public offering of Common Stock. Each share of Series D Preferred Stock issuable upon exercise of the right to purchase would have been convertible into shares of the Issuer's common stock as described in footnote (8) above.
- [F2]The shares are held by Skyline Venture Partners Qualified Purchaser Fund IV L.P. ("Skyline"). John G. Freund, M.D. and Yasunori Kaneko, M.D. are Managing Directors of Skyline Venture Management IV, LLC, the sole general partner of Skyline, and may be deemed to share voting and dispositive power over the shares held by Skyline. Each of Drs. Freund and Kaneko disclaim beneficial ownership of such shares, except to the extent of their pecuniary interest therein.
- [F3]Upon the closing of the Issuer's initial public offering, each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.19 basis without payment of further consideration and with no expiration date.
- [F4]Reflects a 1-for-15.87 reverse stock split effected on October 6, 2014.
- [F5]Upon the closing of the Issuer's initial public offering, each share of Series A-1 Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.22 basis without payment of further consideration and has no expiration date.
- [F6]Upon the closing of the Issuer's initial public offering, each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.23 basis without payment of further consideration and has no expiration date.
- [F7]Upon the closing of the Issuer's initial public offering, each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1-for-1.23 basis without payment of further consideration and has no expiration date.
- [F8]Upon the closing of the Issuer's initial public offering, each share of Series D Convertible Preferred Stock automatically converted into Common Stock on a one-for-one basis (without payment of further consideration and with no expiration date) plus an additional 6,158 incremental shares as a result of an adjustment as provided for in the Company's certificate of incorporation.
- [F9]Upon the closing the Issuer's initial public offering, Skyline exercised their warrants to purchase common stock on a net issue basis resulting in the net issuance of 65,722 shares of common stock.
Documents
Issuer
PROTEON THERAPEUTICS INC
CIK 0001359931
Entity typeoperating
Related Parties
1- filerCIK 0001359931
Filing Metadata
- Form type
- 4
- Filed
- Oct 28, 8:00 PM ET
- Accepted
- Oct 29, 7:35 PM ET
- Size
- 33.0 KB